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http://dx.doi.org/10.1016/j.ccell.2014.10.005SUMMARYPatients with germline fumarate hydratase (FH) mutation are predisposed to develop aggressive kidney
cancer with few treatment options and poor therapeutic outcomes. Activity of the proto-oncogene ABL1 is
upregulated in FH-deficient kidney tumors and drives a metabolic and survival signaling network necessary
to cope with impaired mitochondrial function and abnormal accumulation of intracellular fumarate. Excess
fumarate indirectly stimulates ABL1 activity, while restoration of wild-type FH abrogates both ABL1 activa-
tion and the cytotoxicity caused by ABL1 inhibition or knockdown. ABL1 upregulates aerobic glycolysis
via the mTOR/HIF1a pathway and neutralizes fumarate-induced proteotoxic stress by promoting nuclear
localization of the antioxidant response transcription factor NRF2. Our findings identify ABL1 as a pharma-
cologically tractable therapeutic target in glycolytically dependent, oxidatively stressed tumors.INTRODUCTION
Cancers that depend on altered metabolic programs and on
upregulated stress response pathways need to cope with the
consequences of deregulated metabolism. Utilizing genetically
defined cancers with well-characterized metabolic adaptations
provides a unique opportunity to identify mechanism-based
therapeutic interventions. Hereditary kidney cancers provide
models that are particularly well suited for this purpose, as two
types of kidney cancer are characterized by mutation of the
tricarboxylic acid (TCA) cycle genes, fumarate hydratase (FH)
and succinate dehydrogenase (SDH), respectively. Inactivation
of either enzyme disrupts mitochondrial respiration and pro-
motes dependence on aerobic glycolysis, a characteristic of
aggressive kidney cancer (Linehan and Rouault, 2013; Cancer
Genome Atlas Research Network, 2013). Mutations in FH areSignificance
Patients with germline fumarate hydratase (FH) mutation are
treatment options and poor therapeutic outcomes. An unbias
identified the tyrosine kinase inhibitor vandetanib to be high
revealed that vandetanib-mediated cytotoxicity is ABL1 depe
specimens and tumor-derived cell lines and simultaneously p
defense. In animal xenograft studies, an 8-week regimen of d
Thus, inhibiting ABL1 may provide a clinically feasible strategy
ney cancer and, perhaps, additional glycolytic, oxidatively stre
840 Cancer Cell 26, 840–850, December 8, 2014 ª2014 Elsevier Inc.found in the germline of patients with hereditary leiomyomatosis
and renal cell carcinoma (HLRCC), a hereditary cancer syn-
drome in which affected individuals are at risk for developing
cutaneous and uterine leiomyomas and a highly aggressive
form of type 2 papillary kidney cancer (Grubb et al., 2007). No
effective form of therapy is currently available for patients with
advanced FH-deficient kidney cancer.
FH-deficient kidney cancers and their cell line models are
highly glycolytic and display increased glucose dependence,
lactate production, elevated levels of the hypoxia-stimulated
transcription factor HIF1a and decreased activity of AMP-acti-
vated kinase (AMPK) (Yang et al., 2010; Tong et al., 2011;
Yang et al., 2012). This metabolic adaptation is, at least in part,
a direct consequence of the intracellular accumulation of the on-
cometabolite fumarate (Isaacs et al., 2005; Frezza et al., 2011;
Tong et al., 2011). By inhibiting hypoxia-inducible factor (HIF)predisposed to develop aggressive kidney cancer with few
ed drug screen using FH-deficient tumor-derived cell lines
ly cytotoxic both in vitro and in vivo. Mechanistic studies
ndent. ABL1 is activated in both FH-deficient kidney tumor
romotes aerobic glycolysis and NRF2-mediated antioxidant
rug treatment resulted in 13 months of tumor-free survival.
for treating patients with highly aggressive FH-deficient kid-
ssed tumors.
Figure 1. Vandetanib Inhibits ABL1 Activity In Vitro
(A) Cell viability following vandetanib treatment of FH-deficient cells (UOK262,
UOK268) and their paired molecularly restored counterparts (UOK262WT and
UOK268WT).
(B) Effect of vandetanib (VAN) (5 nM) on UOK262 invasiveness monitored in
real time using the xCELLingence platform. a.u., arbitrary units. CTL, control.
(C) HIF1a expression after vandetanib treatment or siRNA-mediated silencing
of ABL1 (16 hr in each case) was assessed by ELISA in UOK262 and UOK268
cells (MSD Technology, 20 mg of protein per sample).
(D) Phosphorylation of mTOR and S6K is decreased following vandetanib
treatment and siRNA-mediated silencing of ABL1 as visualized by immuno-
blotting. Phosphorylation of CRKII is used as a marker of ABL1 activity. Van-
detanib was used at 20 nM; imatinib (IMA) was used at 200 nM.
(E and F) ABL1 kinase activity was determined by in vitro assay using ABL1
immunoprecipitated for either UOK262 or UOK268 cells (E) or purified protein
(F). Immunoprecipitated ABL1 or purified protein was incubated for 1 hr at
30C with vandetanib (20 nM) or imatinib (200 nM) in the presence of ATP
(10 mM) and ABL1 substrate (see Experimental Procedures). ABL1 kinase
activity was measured by quantifying substrate phosphorylation.
(G) Steady-state phosphorylation of ABL1 in cells following vandetanib treat-
ment was visualized by immunoblotting.
*p < 0.05. Data are displayed as the mean ± SD. See also Figure S1 and
Table S1.
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Inhibiting ABL1 in HLRCC Cancerprolyl hydroxylase, fumarate stabilizes HIF1a, which leads to the
transcription of multiple genes, including those that encode for
glucose transporters 1 and 4 (Glut1, Glut4), and vascular endo-
thelial growth factor (VEGF).
Although HIF1a transcriptional activity and expression is
increased in HLRCC tumors (Koivunen et al., 2007; Isaacs
et al., 2005), their high energetic demands and increased glyco-
lytic activity cause redox homeostasis to become unbalanced
due to elevated production of reactive oxygen species (ROS)
(Sudarshan et al., 2009; Sullivan et al., 2013). To survive this
proteotoxic stress, FH-deficient kidney cancer cells utilize the
oxidative branch of the pentose phosphate pathway to driveCaNADPH production and glutathione synthesis (Yang et al.,
2013). Excess fumarate also stabilizes the master regulator of
the antioxidant response, the transcription factor nuclear factor
(erythroid-derived 2)-like 2 (NFE2L2, or NRF2) (Ooi et al., 2011;
Adam et al., 2011). NRF2 activation in cancer has been reported
to be either beneficial or detrimental, depending on the context
and/or the tumor type (Sporn and Liby, 2012). In HLRCC tumors,
NRF2 activation appears to be critical for tumor growth and sur-
vival (Frezza et al., 2011; Ooi et al., 2011; Adam et al., 2011).
Although the FH mutation has been reported almost solely in
HLRCC cancers, reduced FH activity has been found in other
cancers, including clear cell kidney cancer (Sudarshan et al.,
2011), and induction of pseudohypoxia and deregulated redox
homeostasis are common features of many aggressive epithelial
cancers (Denko, 2008; Cairns et al., 2011). While several studies
have identified components of these pathways as potential mo-
lecular targets in FH-deficient tumors (Xie et al., 2009; Sourbier
et al., 2010; Frezza et al., 2011), identification of a clinically trac-
table therapy forHLRCCcancer patients remains an unmet need.
In the present study, we used an unbiased drug screen to identify
therapeutic strategies targeting the deregulatedmetabolism and
upregulated stress response pathways of HLRCC cancer.
RESULTS
Drug Screening Identifies Vandetanib as Highly
Cytotoxic for FH-Deficient HLRCC Kidney Cancer Cells
In order to find therapeutic strategies for patients with highly
aggressive HLRCC-associated kidney cancer, we utilized the
HLRCC-derived UOK262 cell line cultured in pyruvate-free me-
dia to screen a panel of 17 agents targeting diverse signaling
pathways (Table S1 available online). The tyrosine kinase inhibi-
tor vandetanib (half maximal inhibitory concentration [IC50] =
16 nM) proved to be, by far, the most potent compound tested.
Vandetanib displayed synthetic lethality for FH-deficient cells;
stable reintroduction of wild-type FH into two independently
derived HLRCC cell lines (UOK262 and UOK268) abrogated its
cytotoxicity (Figure 1A).
We reported previously that HIF1a expression is necessary to
maintain the invasive phenotype of HLRCC cells (Tong et al.,
2011). Vandetanib fully inhibited the invasiveness of UOK262 cells
(Figure 1B; Figure S1A) and markedly decreased their HIF1a
protein expression to levels comparable to those seen in wild-
type FH-restored cells (Figure 1C), but its mechanism of action
involved neither protein degradation nor modulation of HIF1a
mRNA levels (Figures S1B and S1C). These data suggested that
vandetanib may affect HIF1a translation, a process regulated by
the protein kinasemammalian target of rapamycin (mTOR) (Powis
and Kirkpatrick, 2004). Indeed, we found that steady-state phos-
phorylation of mTOR and its downstream target S6 kinase were
markedly decreased following vandetanib treatment (Figure 1D).
Since Abelson (ABL) murine leukemia viral oncogene homolog
1 (ABL1) is reported to regulate mTOR (Cilloni and Saglio, 2012;
Kim et al., 2005; Markova et al., 2010) and vandetanib potently
inhibits ABL1 in vitro (Davis et al., 2011; Karaman et al., 2008),
we asked whether vandetanib-mediated inhibition of the
mTOR/HIF1a pathway might be phenocopied by ABL1 knock-
down. Using UOK262 cells in which ABL1 was silenced with
small interfering RNA (siRNA), we confirmed that reducedncer Cell 26, 840–850, December 8, 2014 ª2014 Elsevier Inc. 841
Figure 2. Antitumor Activity of Vandetanib Is ABL1 Dependent
(A) Assessment of ABL1 activation status in HLRCC tumor specimens was
performed by immunoblotting for phosphorylated ABL1 following immuno-
precipitation of ABL1 protein from tissue lysates. The intensity ratio of phos-
phorylated ABL1 to total ABL1 was assessed by densitometric analysis. IgG,
immunoglobulin G.
(B) Assessment of ABL1 activation status in a panel of cell lines was performed
as in (A).
(C) Rescue with various infected murine ABL proteins was performed 72 hr
after lentiviral infection of UOK262 cells with ABL-targeted miRNA (miABL).
Scrambled miRNA (miSCR) was used as anmiRNA control, and empty pBABE
vector (BABE) served as the control for infection with the various murine ABL
contructs. Murine ABL constructs included wild-type (WT), kinase-dead
(K290M), kinase inhibitor-resistant (T315I), and constitutively active ABL
(P131I). Cell viability in presence and absence of vandetanib was assessed
(24 hr, 50 nM; VAN: vandetanib).
(D) Immunoblot showing reduction in ABL1 protein expression 72 hr post-
miABL infection, and subsequent expression level of reintroduced murine ABL
proteins. mTOR phosphorylation status is correlated with expression of
competent ABL1 protein.
(E) Silencing of ABL1 with siRNA is cytotoxic for FH-deficient cells.
(F) Importance of ABL1 for soft agar colony growth of FH-deficient cells was
assessed by measuring the number of colonies visible 4 weeks after seeding
with cells treated as shown. IMA, imatinib; CTL, control.
*p < 0.05; **p < 0.001. Data are displayed as the mean ± SD. See also
Figure S2.
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Inhibiting ABL1 in HLRCC Cancerexpression of ABL1, like vandetanib treatment, inhibited HIF1a
expression and mTOR activity (Figures 1C and 1D; Figure S1D).
Next, we confirmed that vandetanib and the ABL1 inhibitor ima-
tinib inhibited the in vitro kinase activity of endogenous ABL1 that
was immunopurified from both FH-deficient renal cell carcinoma
cell lines (UOK262 andUOK268), aswell as the activity of purified842 Cancer Cell 26, 840–850, December 8, 2014 ª2014 Elsevier Inc.ABL1 protein (Figures 1E and 1F, respectively). These data were
confirmed by assessing the phosphorylation status of CRKII,
a substrate of ABL1 (Figure 1D), and by determining the phos-
phorylation status of ABL1 immunopurified from UOK262 and
UOK268 cell lines previously treated for 4 hr with vandetanib
(Figure 1G). Furthermore, ABL1-specific siRNA reduced HIF1a
expression in two HLRCC-derived cell lines to levels comparable
to those achieved with vandetanib treatment or by restoration of
wild-type FH (Figure 1C). Finally, nilotinib and ponatinib, two
structurally distinct ABL1 inhibitors, were equipotent with vande-
tanib in inhibiting the growth of UOK262 cells, and their toxicity
was markedly ameliorated by restoration of wild-type FH (Fig-
ure S1E). Notably, the growth inhibitory activity of these ABL1
inhibitors was reduced in medium containing pyruvate (Fig-
ure S1F). Finally, using an in vitro kinase assay, we found that
these three TKIs displayed similar potency in inhibiting the activ-
ity of purified ABL1 (vandetanib IC50 = 15 nM, nilotinib IC50 =
4 nM, and ponatinib IC50 = 17 nM; Figure S1G), consistent with
our hypothesis that ABL1 may be an important target in FH-defi-
cient tumor cells. However, we cannot exclude the possibility
that an off-target effect of vandetanibmay fortuitously contribute
to its activity in this tumor model.
ABL1: A Therapeutic Target in FH-Deficient Tumor Cells
The ABL family of nonreceptor tyrosine kinases, comprising
ABL1 and ABL2, affects diverse signaling pathways involved in
cell growth, invasion, and migration. Activation of ABL1 and
ABL2 has been detected in a number of different cancers
(Greuber et al., 2013). Although the role of oncogenic BCR-
ABL fusion protein has been extensively studied in hematologic
malignancies (Cilloni and Saglio, 2012), much less is known
about the physiological and/or pathological role of wild-type
ABL1. Based on the preceding data, we immunoprecipitated
ABL1 from protein lysates of five HLRCC tumors surgically
removed from three patients, as well as from lysates of normal
tissues, and we compared ABL1 phosphorylation normalized
to total immunoprecipitated ABL1 protein as an indicator of its
activation state (Figure 2A). The ABL1 activation state in five of
five tumor specimens was significantly greater than that in the
normal tissues. We performed a similar comparison in two
HLRCC-derived cell lines and in their wild-type FH-restored
counterparts (Figure 2B). Constitutive ABL1 phosphorylation,
while clearly evident in both HLRCC-derived cell lines, was
markedly reduced on restoration of wild-type FH (total and phos-
pho-ABL1 levels in human embryonic kidney 293 [HEK293] kid-
ney cells are included for comparison), although this did not
affect the expression of total ABL1 protein. We also assessed
the phosphorylation status of ABL1 in skin and uterine leiomyo-
mas, two classical manifestations of HLRCC disease, compared
with their normal counterparts (Figures S2A and S2B). ABL1
phosphorylation was elevated in skin leiomyomas but not in uter-
ine leiomyomas, suggesting that treatment of these manifesta-
tions might require alternative targeting approaches.
Given these findings, we investigated next whether the cyto-
toxicity of vandetanib in FH-deficient tumor cells was ABL1
dependent. Classical rescue experiments were performed
following ABL1 knockdown in UOK262 cells by lentiviral infec-
tion of microRNA (miRNA) targeting human ABL1 (miABL1;
a scrambled miRNA, miSCR, was used as an miRNA control)
Figure 3. ABL1 Supports Aerobic Glycolysis in FH-Deficient Tumor
Cells
(A) Expression of the glucose transporters Glut1 and Glut4 following vande-
tanib treatment (24 hr) in UOK262 cells.
(B) Glucose uptake was measured in UOK262 cells using the nondegradable
fluorescent glucose analog 2-NBDG (20 mM) after vandetanib (20 nM, 16 hr) or
imatinib (200 nM, 16 hr) treatment, or after silencing either ABL1 or HIF1a.
(C) Lactate secretion after vandetanib treatment (20 nM, 16 hr).
(D) The effect of ABL1 silencing or inhibition on aerobic glycolysis in UOK262
cells was measured by recording the extracellular acidification rate (ECAR, a
surrogate for lactate secretion) in a Seahorse Bioanalyzer.
VAN, vandetanib; IMA, imatinib; CTL, control. *p < 0.05. Data are displayed as
the mean ± SD. See also Figure S3.
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ABL constructs, not recognized by miABL1, were then infected,
and their ability to rescue endogenous ABL1 knockdown or its
pharmacologic inhibition was examined. These constructs
included wild-type (WT) ABL1, kinase-dead ABL1 (K290M), tyro-
sine kinase inhibitor (TKI)-resistant ABL1 (T315I), and constitu-
tively active ABL1 (P131L) (Figures 2C and 2D) (Smith-Pearson
et al., 2010; Yogalingam and Pendergast, 2008). Infection with
empty pBABE plasmid (‘‘BABE’’) served as a control. Using puri-
fied proteins in an in vitro kinase assay, we confirmed that ABL1-
T315I was resistant to vandetanib (Figure S2C). Knockdown of
endogenous ABL1 on infection with miRNA significantly de-
creased cell viability (approximately 50%) at 24 hr, while simulta-
neous expression of WT, T315I, and P131L murine ABL proteins
restored cell viability to control (or miSCR-infected) levels (Fig-
ure2C). In contrast, kinase-deadABL1expressiondid not restore
cell viability, supporting theABLdependenceof this phenotype. It
is important to note that vandetanib did not cause additional
toxicity inmiABL1-treated cells expressing either empty plasmid,Cakinase-dead ABL1, TKI-resistant ABL1, or constitutively active
ABL1. However, vandetanib produced significant cytotoxicity in
cells infected with miSCR and in cells infected with both miABL1
andWTmurine ABL1. Consistent with these data, the silencing of
endogenous ABL1 in UOK262 cells with two distinct siRNAs
dramatically decreased cell viability in the absence of vandetanib
(Figure 2E). Finally, like vandetanib cytotoxicity, the cytotoxicity
incurred by ABL1 knockdown was abrogated by restoration of
WT FH in UOK262 cells (Figures S2D and S2E). In both
UOK262 and HEK293 cells, ABL1 knockdown on miABL1 infec-
tion markedly reduced mTOR phosphorylation. Reexpression of
WT, TKI-resistant, or constitutively active ABL1, but not kinase-
dead ABL1, was able to rescue this phenotype (Figure 2D; Fig-
ure S2F). Notably, the infected murine ABL1 proteins were ex-
pressed at levels similar to endogenous ABL1 in both cell lines.
To assess the importance of ABL1 in maintaining the tumo-
rigenic phenotype of FH-deficient cells, we measured their
anchorage-independent growth and invasiveness after ABL1 in-
hibition or silencing. These data show that ABL1 expression and
activity are necessary to sustain the clonogenicity and invasive
potential of FH-deficient tumor cells (Figure 2F; Figure S1A).
ABL1 Promotes Aerobic Glycolysis
Based on our data linking ABL1 with HIF1a expression (Fig-
ure 1C), we investigated whether ABL1 inhibition affected the
aerobic glycolysis on which FH-deficient cells depend for gener-
ation of ATP and cellular building blocks (Yang et al., 2010; Tong
et al., 2011). First, we found that vandetanib significantly de-
creased expression of the glucose transporters Glut1 and
Glut4 in UOK262 cells (Figure 3A), concomitant with decreased
glucose uptake and lactate secretion (Figures 3B and 3C,
respectively). Transient silencing of ABL1 or HIF1a decreased
glucose uptake to a similar degree (Figure 3B; Figure S3A). To
confirm that ABL1 promotes aerobic glycolysis, we assessed
the impact of ABL1 modulation on the extracellular acidification
rate (ECAR, a surrogate for lactate secretion). In agreement with
our earlier results, silencing or pharmacologic inhibition of ABL1
significantly decreased ECAR in UOK262 cells (Figure 3D).
Consistent with a relationship between ABL1 activity and gly-
colysis, vandetanib concomitantly inhibited both ABL1 activity
(steady-state ABL1 phosphorylation) and glucose uptake in
UOK150, a glycolytic clear-cell kidney cancer cell line estab-
lished from a non-HLRCC kidney cancer harboring an inactivat-
ing VHL mutation (Sourbier et al., 2012) (Figures S3B and S3C).
Vandetanib Inhibits ABL1, Glycolysis, andHLRCCTumor
Growth In Vivo
In order to visualize the dynamic impact of vandetanib on
HLRCC metabolism in vivo, we used magnetic resonance spec-
troscopic imaging (MRSI) to monitor the metabolism of intrave-
nously injected hyperpolarized [1-13C] pyruvate, as previously
described (Golman et al., 2006; Chen et al., 2007). MRSI detects
increased conversion of pyruvate to lactate in tumors, most
notably in those characterized by a high rate of glycolysis and
impaired oxidative phosphorylation. As shown in Figure 4A,
in vivo imaging of untreated UOK262 xenografts (day 0) revealed
a high lactate/pyruvate ratio, whereas vandetanib treatment
(day 2) significantly suppressed the conversion of pyruvate to
lactate in tumors without affecting tumor perfusion (Figures 4Ancer Cell 26, 840–850, December 8, 2014 ª2014 Elsevier Inc. 843
Figure 4. Vandetanib Inhibits HLRCC Tumor
Growth, ABL1, and Glycolysis In Vivo
(A) 13C-hyperpolarized imaging of mice harboring
UOK262 xenografts before and 2 days after
treatment with vandetanib. The images on the left
display representative nuclear magnetic reso-
nance images, and the images on the right
display representative images of the lactate/py-
ruvate ratio.
(B) Quantification of lactate/pyruvate ratios from
data obtained in (A). Averaged measurements
obtained from five animals in each group were
used.
(C) Growth of UOK262 xenografts treated once
weekly with vehicle (DMSO/PBS) or vandetanib
(100 mg/kg). Right panel: averaged tumor volume
of two independent experiments taken after
7 weeks of treatment.
(D) ABL1 kinase activity was measured by kinase
assay after immunopurification of ABL1 protein
from tumor tissues excised from vehicle-treated
and vandetanib-treated mice 2 days posttreat-
ment. VAN, vandetanib.
*p < 0.05; **p < 0.01. Data are displayed as the
mean ± SD. See also Figure S4.
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detanib inhibits tumor glycolysis in vivo.
Next, we assessed the antitumor efficacy of vandetanib in the
same HLRCC murine xenograft model. As shown in Figure 4C,
vandetanib (100 mg/kg, once weekly, intraperitoneally [i.p.])
caused marked tumor regression in 80% (12 of 15, two indepen-
dent experiments) of treated mice. When we interrogated the
molecular effects of vandetanib in vivo, we found that the activa-
tion status of ABL1 was significantly reduced after 2 days in
tumors excised from vandetanib-treated mice compared with
vehicle-treated animals (Figure 4D), as well as after 10 weeks
of treatment (Figure S4B). Also, similar to earlier in vitro observa-
tions, activity of the mTOR/HIF1a pathway in these tumors
(including HIF1a expression, Glut1 expression, VEGF-A level in
tumor tissue and in plasma, and phospho-S6K) was decreased
in vandetanib-treated mice after 2 days (Figure S4A), as well as
after 10 weeks of treatment (Figures S4C–S4F). After 10 weeks
of treatment, tumors from vandetanib-treated mice were also
more apoptotic and displayed less activation of EGFR family
and VEGF receptor kinases, compared with tumors excised
from vehicle-treated animals (Figures S4G and S4H).
Fumarate-Mediated ABL1 Activation Upregulates
NRF2 Nuclear Localization and Transcriptional Activity
In Vitro and In Vivo
The constitutively elevated level of phosphorylated ABL1 in
HLRCC cell lines is reversed by restoration of WT FH expression844 Cancer Cell 26, 840–850, December 8, 2014 ª2014 Elsevier Inc.(see Figure 2B), and the in vitro kinase
activity of ABL1 immunopurified from
HLRCC cells is significantly greater than
that of the kinase immunopurified from
FH-restored HLRCC cells (Figure 5A).
Therefore, we examined whether intracel-
lular accumulation of fumarate influencedABL1 kinase activity, either directly or indirectly. We observed
that treatment of cells expressing functional FH protein
(HEK293 or UOK262WT) with a cell-permeable form of fumarate
(dimethylfumarate; DMF) resulted in increased ABL1 phosphor-
ylation (Figure 5B). However, neither fumarate nor DMF were
able to directly stimulate ABL1 in vitro, suggesting that fuma-
rate-mediated ABL1 activation in cells is indirect (Figure S5A).
Since ABL1 is activated by oxidative stress and excess intracel-
lular fumarate increases ROS (Sudarshan et al., 2009; Sullivan
et al., 2013), fumarate-induced ABL1 activation may be ROS
dependent. Consistent with this model, treatment of UOK262
cells with the ROS scavenger N-acetylcysteine (NAC) concur-
rently reduced both steady-state ABL1 phosphorylation and
cellular ROS level (Figures S5B and S5C). However, we cannot
exclude the possibility that additional factors may contribute to
the increased activation state of ABL1 in these tumor cells.
Accumulation of intracellular fumarate has been shown to sta-
bilize expression of the antioxidant response transcription factor
NRF2 via inactivation of its endogenous inhibitor KEAP1 (Adam
et al., 2011; Ooi et al., 2011). Since the Src kinase family is re-
ported to modulate NRF2 nuclear translocation (Jain and
Jaiswal, 2006; Shelton and Jaiswal, 2013), we examinedwhether
vandetanib affects this process in FH-deficient tumor cells. By
evaluating nuclear and cytoplasmic fractions prepared from
drug-treated and control cells for NRF2 content, we observed
that vandetanib caused a time-dependent redistribution of
NRF2 from nucleus to cytosol that was complete within 6 hr
Figure 5. ABL1 Coordinates NRF2 Antioxidant Response In Vitro
(A) Basal in vitro ABL1 kinase activity in UOK262WT and UOK262 cells
(normalized to total protein).
(B) Effect of intracellular fumarate accumulation on ABL1 activity in HEK293
and UOK262 cells (Fum, fumarate; 0.25 mM, 4 hr). IgG, immunoglobulin G.
(C–E) The impact of vandetanib on NRF2 nuclear/cytoplasmic distribution was
assessed by immunoblotting of both nuclear and cytoplasmic extracts (C) and
by confocal immunofluorescence microscopy (D–E). Original magnification,
633; scale bar, 25 mm. CTL, control.
(F) NRF2 transcriptional activity was assessed in HEK293 cells following
treatment with vandetanib (VAN, 50 nM, 4 hr) and/or DMF (*, significance
compared to CTL; #, significance compared to DMF-induced NRF2 tran-
scriptional activity) using a NRF2-responsive luciferase reporter assay and
normalized to cotransfected Renilla luciferase.
(G) The role of ABL1 in regulating NRF2 transcriptional activity was assessed
as in (F) following transient silencing of ABL1 using siRNA.
(H) NQO1 expression in UOK262 cells after vandetanib (VAN) or ABL1
silencing. IMA, imatinib.
#p < 0.05; *p < 0.05. Data are displayed as the mean ± SD. See also Figure S5.
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immunofluorescence microscopy performed 6 hr after vandeta-
nib (20 nM) treatment (Figures 5D and 5E). Redistribution of
NRF2 from nucleus to cytosol should result in decreased tran-
scriptional activity. Using a luciferase-based NRF2 reporter
assay, we found that DMF stimulated, while vandetanib in-
hibited, NRF2 transcriptional activity (Figure 5F). Notably, NAC
treatment that reduced ROS level and ABL1 activity (see Figures
S5B and S5C) also caused a significant reduction in DMF-stim-
ulated NRF2 transcriptional activity (Figure S5D). Using the same
assay, we confirmed that silencing of ABL1 abrogated DMF-Cainduced NRF2 transcriptional activity (Figure 5G). Taken
together, these data are consistent with a role for ABL1 in sup-
porting NRF2-mediated transcription in response to elevated
intracellular fumarate levels and for ROS in mediating the
fumarate-dependent increase in NRF2 activity.
HLRCC tumor cells constitutively express high levels of ROS,
and ROS-inducing agents are particularly cytotoxic to these cells
(Sourbier et al., 2010). Because NRF2 plays a critical role in
cellular defense against ROS (Sporn and Liby, 2012), we tested
whether the vandetanib sensitivity of these cells might be
affected by cellular ROS level. We pretreated UOK262 cells
with NAC for 2 hr prior to treatment with vandetanib for an addi-
tional 16 hr. NAC pretreatment did not itself affect cell viability,
but it significantly protected the cells from vandetanib toxicity
(Figure S5E). Notably, the growth inhibitory activity of ABL1-tar-
geting TKIs is also markedly compromised by cell culture in py-
ruvate-containing medium (Figure S1F), and several reports
identify pyruvate as a ROS scavenger (Sudarshan et al., 2009;
Babich et al., 2009). Consistent with these findings, cell culture
in pyruvate-containing medium significantly reduced DMF-
induced NRF2 activity (data not shown).
Since ABL1 also promotes HIF1a-mediated glycolysis (vide
supra), we asked whether inhibition of HIF1a per se contributed
to cell death in this model. First, based on data from our cell
screen, both LY294002 and rapamycin were significantly less
effective in inhibiting cell growth or causing cytotoxicity than
was vandetanib (Table S1). Furthermore, NAC reduced HIF1a
expression as effectively as did vandetanib, but with no toxicity,
indicating that inhibition of NRF2 without relief from the under-
lying oxidative stress is at least a necessary, if not sufficient,
determinant of vandetanib toxicity (Figures S5E and S5F). This
possibility is consistent with our earlier findings that DMF-sti-
mulated NRF2 activity is at least partially ROS dependent. In
support of this hypothesis, both ABL1 inhibition and silencing
decreased expression of the endogenous NRF2 transcriptional
target NQO1 (Figure 5H), which is strongly upregulated in
HLRCC tumor tissue (Figure S5H) (Adam et al., 2011). Finally,
silencing of NRF2 with two independent siRNAs caused signifi-
cant cytotoxicity in UOK262 cells, a phenotype that was
reversed in UOK262WT (Figure S5G).
To assess whether these findings are recapitulated in vivo, we
examined the effect of vandetanib on NQO1 expression in
HLRCC xenografts. Its expression was significantly decreased
in UOK262 xenografts excised from mice treated with vandeta-
nib (Figure S5I; tissues from the animal study described in
Figure 4).
AMPK Activation Inhibits NRF2 Activity Additively with
Vandetanib to Inhibit FH–/– RCC Tumor Growth
SIRT1-mediated deacetylation of NRF2 is reported to inhibit its
transcriptional activity (Kawai et al., 2011). Since AMPK posi-
tively regulates SIRT1 and is constitutively hypoactivated in
FH-deficient tumors (Tong et al., 2011; Fulco and Sartorelli,
2008), we asked whether pharmacologic activation of AMPK in
these cells might enhance SIRT1 deacetylase activity to inhibit
NRF2 independently from vandetanib. First, we assessed the ef-
fect of AMPKmodulation on NRF2 transcriptional activity using a
luciferase-reporter assay. The AMPK activators metformin and
AICAR decreased DMF-stimulated NRF2 activity in HEK293ncer Cell 26, 840–850, December 8, 2014 ª2014 Elsevier Inc. 845
Figure 6. Metformin Sensitizes HLRCC
Xenografts to Vandetanib
(A) NRF2 transcriptional activity was assessed
in HEK293 cells following treatment with the
AMPK activators metformin (METF; 1 mM, 6 hr),
and AICAR (50 mM, 6 hr) in the presence
and absence of DMF (0.25 mM). a.u., arbitrary
units.
(B) Metformin and SIRT1 knockdown exert
opposing effects on NRF2 acetylation status as
visualized by immunoblotting with an antibody
recognizing acetylated lysine (AcK) following
immunoprecipitation of NRF2. CTL, control.
(C) Effect of vandetanib (VAN, 5 nM) and metfor-
min (5 mM) treatment, singly or together, on NRF2
transcriptional activity.
(D) Effect of combining metformin (5 mM) and
vandetanib (VAN, 5 nM) on UOK262 viability after
24 hr.
(E) Effect of metformin and vandetanib alone
or in combination on UOK262 xenograft growth in
mice. This study used 1/10 of the vandetanib dose
used in the experiment shown in Figure 4.
(F) Averaged data from two independent experi-
ments identical to the experiment shown in (E)
(eight animals per group).
(G) Tumor regressions achieved with vandetanib/
metformin 8-week treatment regimen are durable.
Graph shows percent survival over 13 months of
mice treated for 8 weeks with the vandetanib/
metformin combination as shown in (E) and (F),
compared to vehicle-treated animals. ø denotes a
mouse that died following pelvic prolapse. No tu-
mor was found at necropsy.
#p < 0.05; *p < 0.05. Data are displayed as the
mean ± SD. See also Figure S6.
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Inhibiting ABL1 in HLRCC Cancerand UOK262 cells, while knockdown/inhibition of SIRT1 with
siRNA or nicotinamide, respectively, had the opposite effect
(although the increased NRF2 activity remained sensitive to van-
detanib) (Figure 6A; Figures S6A and S6B). Consistent with these
data, metformin treatment decreased NRF2 acetylation in
UOK262 cells, while silencing SIRT1 had the opposite effect
(Figure 6B).
Next, we examined whether combining metformin and vande-
tanib caused additive inhibition of NRF2. Data obtained using a
luciferase reporter in HEK293 cells and by monitoring endoge-
nous NQO1 expression in UOK262 cells suggested that this is
the case (Figure 6C; Figure S6C). Supporting these obser-
vations, we found that metformin, at a concentration lacking
single-agent toxicity, significantly decreased the viability of
UOK262 cells when combined with a suboptimal concentration
of vandetanib (Figure 6D). Since both vandetanib and metformin
have multiple effects in cells, we confirmed that their additive
impact on NRF2 was due to ABL1 inhibition combined with
AMPK activation. Thus, both metformin and AICAR cooperated
with knockdown of ABL1 to markedly reduce cell viability, while,
in the absence of ABL1 silencing, neither drug was effective.
Furthermore, nilotinib displayed greater cytotoxicity at lower
concentrations in combination with metformin, compared with
its single-agent activity (Figures S6D–S6F). Finally, in vivo anal-846 Cancer Cell 26, 840–850, December 8, 2014 ª2014 Elsevier Inc.ysis confirmed that low-dose vandetanib (10 mg/kg, once
weekly; 1/10 of the dose used in the experiment shown in Fig-
ure 4) combined with metformin (5 mg/kg, once weekly) induced
complete tumor regression within 8 weeks of treatment initiation
in 100% of treated mice (Figures 6E and 6F; 12 of 12 mice from
two independent experiments). No tumor regressions were seen
in mice treated with the single agents at these doses. Nine of ten
mice treated with the vandetanib/metformin combination re-
mained tumor free for more than 13 months after treatment
cessation, while vehicle-treated mice all had to be sacrificed
by 8 weeks due to tumor size (Figure 6G).
DISCUSSION
Loss of FH activity leads to fumarate accumulation that sustains
both aerobic glycolysis and NRF2-mediated antioxidant re-
sponses (Isaacs et al., 2005; Ooi et al., 2011; Adam et al.,
2011). Although both pathways are critical for HLRCC cancer
growth in vivo, a strategy to simultaneously target these pro-
cesses has eluded investigators. Here, we show that ABL1, a
nonreceptor tyrosine kinase involved in numerous biological pro-
cesses including cell proliferation, cell migration, metabolism,
and apoptosis (Greuber et al., 2013), is indirectly activated by
increased fumarate, likely as a consequence of elevated ROS
Figure 7. ABL1 Is a Key Regulator of Both Aerobic Glycolysis and the Antioxidant Stress Response in HLRCC Tumors
The model depicts a proposed dual role for ABL1 in supporting FH-deficient tumor cell viability and energy metabolism. By stimulating mTOR activity to increase
HIF1a translation, ABL1 promotes aerobic glycolysis, thus enabling the tumor cells to meet their energetic needs. Simultaneously, ABL1 also facilitates NRF2
nuclear localization, thus supporting its transcriptional activity, which allows tumor cells to buffer the high oxidative stress that is a consequence of excess
fumarate accumulation. See also Figure S7.
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HLRCC tumor cells (Figure 7). Using an unbiased screen, we
identified the TKI vandetanib as having particular potency in an
HLRCC-derived cell line in vitro, and we found that vandetanib
efficacy was compromised by restoration of WT FH activity in
these cells. Although vandetanib inhibits several other kinases
in addition to ABL1, we found that ABL1 knockdown using two
different siRNAs as well as a human ABL1-targeted miRNA mi-
micked vandetanib cytotoxicity, as did several other TKIs that
share ABL1 inhibitory activity with vandetanib. In addition, reex-
pression of active murine ABL1 rescued cells from these effects,
and re-expression of TKI-resistant ABL1 abrogated vandetanib
toxicity. Taken together, these data suggest that ABL1 inhibition
accounts for much of the vandetanib effect in HLRCC cells,
although we cannot exclude the possibility that an off-target ef-
fect contributes to the potency of vandetanib in this tumormodel.
A common characteristic of advanced cancer is enhanced
dependence on glucose and on glycolytic metabolism (Vander
Heiden et al., 2009). In this regard, FH-deficient tumor cells,
with their disrupted TCA cycle, are examples of the Warburg ef-
fect and represent a human-derived, genetically defined tumor
model for evaluating therapeutic strategies designed to interdict
these pathways. Although targeting aerobic glycolysis in cancer
has yielded promising results in vitro, in vivo efficacy has been
limited, often because of systemic toxicities. Our present find-
ings show a potential role for ABL1 in modulating mTOR-depen-Cadent HIF1a expression and demonstrate that both vandetanib
and ABL1 knockdown phenocopy several consequences of
HIF1a silencing in HLRCC cells, including reduced HIF1a protein
expression and transcriptional activity, reduced aerobic glycol-
ysis (in vitro and in vivo), and reduced cell invasiveness (Tong
et al., 2011).
Given these data, it is perhaps surprising that LY294002 and
rapamycin were not more active in our in vitro growth inhibi-
tion/cytotoxicity screen (see Table S1). However, HIFmodulation
alone would not be expected to fully correct either the underlying
defect in fumarate metabolism or the resultant accompanying
oxidative stress, phenomena identified in our present study as
key contributors to the cytotoxicity of both vandetanib and
ABL1 knockdown. We previously reported that HLRCC-derived
cell lines express abundant HIF1a as a consequence of both
direct fumarate-mediated inhibition of HIF prolyl hydroxylase
and indirect effects of elevated ROS levels (Isaacs et al., 2005;
Klimova and Chandel, 2008; Sudarshan et al., 2009; Tong
et al., 2011). Highly glycolytic cancers, including HLRCC-associ-
ated kidney cancer, generate excessive ROS and depend on an
efficient oxidative stress response transcriptional program, sug-
gesting that disruption or overwhelming of this machinery may
provide an alternative treatment strategy (Sourbier et al., 2010).
NRF2 is the master transcriptional regulator of the antioxidant
response. Under nonstress conditions, it is sequestered in the
cytoplasm by the adaptor protein, KEAP1, which also facilitatesncer Cell 26, 840–850, December 8, 2014 ª2014 Elsevier Inc. 847
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degradation. In the presence of oxidative stress, cysteine resi-
dues in KEAP1 are oxidized to inactivate the protein, promoting
stabilization of NRF2 in the cytoplasm. In HLRCC cells, elevated
intracellular fumarate inactivates KEAP1 by covalently modifying
its cysteine residues in a process termed succination, resulting in
constitutive stabilization of NRF2 (Adam et al., 2011; Ooi et al.,
2011). NRF2 is also regulated by the protein deacetylase
SIRT1, and Ooi and colleagues recently identified SIRT1 muta-
tions as contributors to NRF2 activation in papillary type II renal
cancer, a sporadic cancer that is histologically similar to HRLCC
(Ooi et al., 2013), suggesting that stabilization and activation of
NRF2-driven antioxidant responses may be important factors
in kidney cancers.
ABL1 is an important, SIRT1-independent determinant of NRF2
nuclear localization and transcriptional activity both in vitro and
in vivo (Figure 7). Our data are consistent with previous studies
in other tumor models reporting that ABL1 is activated by oxida-
tive stress and DNA damage and affects the NRF2-dependent
antioxidant response (Sun et al., 2000; Greuber et al., 2013; Li
et al., 2004). Since aberrant activation of NRF2 signaling occurs
in multiple tumor types (Figure S7A), it is reasonable to speculate
that targeting ABL1 might be a potential therapeutic strategy for
such tumors inaddition toHLRCC-associatedkidneycancer.Pre-
liminary data obtained using a panel of lung cancer cell lines sup-
port this hypothesis (Figures S7B and S7C) and suggest that
expression of NQO1 may be a predictive biomarker of response.
Finally, we found that upregulation of AMPK (constitutively hy-
poactive in HLRCC) (Tong et al., 2011), either as a consequence
of mitochondrial complex I inhibition with metformin or following
treatment with the AMPK activator AICAR, was additive with
ABL1 inhibition in maximally inhibiting NRF2 activity in vitro. The
sensitivity of NRF2 to AMPK activation is likely a consequence
of AMPK-dependent SIRT1 activation, since metformin de-
creased nicotinamide-sensitive NRF2 acetylation. Notably, in an
HLRCC xenograft model, inclusion of metformin (at a clinically
achievable dose) reduced the effective vandetanib concentration
by 90% (compared to single-agent vandetanib administration).
Weekly administration of this drug combination for 8 weeks
caused complete tumor regression in 100% of treated mice and
extended tumor-free survival for more than 1 year after cessation
of treatment.
In summary, our data show that ABL1 is a key, pharmaco-
logically tractable modulator of the cellular stress response to
excess fumarate accumulation. Since ABL1 also supports HIF-
dependent glycolytic metabolism, inhibiting this kinase provides
a clinically viable strategy to simultaneously interfere with aerobic
glycolysis and the antioxidant response pathway, onwhich highly
glycolytic, oxidatively stressed tumors depend for survival.EXPERIMENTAL PROCEDURES
Cell Lines and Cell Culture
UOK262, UOK268, UOK262WT, UOK268WT, and UOK150 cell lines were es-
tablished in the Urologic Oncology Branch from surgically resected tumor
specimens (National Cancer Institute) (Yang et al., 2010, 2012; Anglard
et al., 1992). All other cell lines were purchased fromATCC. Cells were cultured
in high glucose Dulbecco’s modified Eagle medium without pyruvate supple-
mentedwith 10% fetal bovine serum. The cells were harvested or treatedwhen
they reached 70%–80% confluence.848 Cancer Cell 26, 840–850, December 8, 2014 ª2014 Elsevier Inc.Chemical Agents
Vandetanib was generously provided by AstraZeneca. PTHrP-neutralizing
antibody was from Bachem. All other compounds used were from Sigma-
Aldrich or Selleck Chemicals.
Human Tissues
All human tissues were obtained with informed consent from patients enrolled
on a Urologic Oncology Branch Clinical Protocol approved by the institutional
review board of the National Cancer Institute.
ABL1 Kinase Activity Assay
Five nanograms of purified ABL1 protein (Life Technologies) and the peptide
substrate paxillin (Santa-Cruz Biotechnology) were incubated for 1 hr at
30Cwith 10 mMATP in kinase assay buffer. The reaction was stopped by add-
ing denaturing sample buffer, and phosphorylation of the recognition motif I/V/
L-Y-X-X-P/F was assessed by immunoblot analysis. Alternatively, the reaction
was stopped by adding ADP-Glo reagent (ADP-Glo Kinase Assay Kit, Pro-
mega), and kinase activity was assessed following the manufacturer’s
instructions.
ABL1 Constructs and Infection
Murine ABL1 constructs and miRNA targeting human ABL1 (not recognizing
murine ABL) were introduced into HEK293 and UOK262 cells following a pre-
viously described protocol (Smith-Pearson et al., 2010; Yogalingam and Pen-
dergast, 2008), with the following modifications. Briefly, lentiviruses were
generated in HEK293T cells as previously described (Smith-Pearson et al.,
2010; Yogalingam and Pendergast, 2008). Supernatant containing the viral
particles was collected 48 hr posttransfection, aliquoted, and stored at
80C until usage. Five thousand UOK262 or HEK293 cells were plated in
blackview 96-well plates, and 50,000 cells were seeded in six-well plates.
The former were used for viability determination, and the latter were used for
western blotting (see Results). The day after plating, cells were infected with
the different viruses using 1:30 v/v miRNA/media and 1:30 v/v vector/media
per well in the presence of polybrene (8 mg/ml). The media were changed
24 hr postinfection. Forty-eight hours postinfection, cells were treated as in-
dicated in the figures (Figures 1, 2, 3, 5, and 6; Figures S1, S2, and S5–S7).
Seventy-two hours postinfection, protein lysates were harvested for western
blotting or cell viability assays were performed.
Animal Study
All animal experiments were performed on approved protocols and in accor-
dance with the guidelines of the Animal Care and Use Committee of the NIH.
13C MRI of Hyperpolarized 13C-Labeled Pyruvate Metabolism
Samples of [1-13C] pyruvic acid (30 ml) containing 15 mM triarylmethyl radical
and 2.5 mM gadolium chelate ProHance (Bracco Diagnostics) were polarized
at 3.35 T and 1.4 K in a Hypersense DNP Polarizer (Oxford Instruments), ac-
cording to themanufacturer’s instructions. After 40–60min, the hyperpolarized
sample was rapidly dissolved in 4.5 ml of a superheated alkaline buffer
comprising 40 mM HEPES, 30 mM NaCl, and 100 mg/l EDTA. NaOH was
added to the dissolution buffer to adjust pH to 7.4 after mixture with [1-13C] py-
ruvic acid. Hyperpolarized [1-13C] pyruvate solution (12 ml/g body weight) was
intravenously injected through a catheter placed in the tail vein of the mouse.
Hyperpolarized 13CMRI studies were performed on a 7 T scanner (Bruker Bio-
SpinMRI) using a 17mmhome-built 13C solenoid coil placed inside of a saddle
coil for 1H. The 13C 2D spectroscopic images were acquired 30 s after the start
of pyruvate injection from a 28 3 28 mm field of view in a 8 mm coronal slice
through the tumor, with a matrix size of 16 3 16, a spectral width of 8 kHz,
repetition time of 78 ms, and 0.2 ms Gaussian excitation pulse with a flip angle
of 10. The total time required to acquire an image was 20 s.
ATP Assay
ATP levels were determined using the ATPLite Assay (PerkinElmer), following
the manufacturer’s protocol.
Immunofluorescence
Immunofluorescence was performed as previously described (Sourbier et al.,
2013). Briefly, 5,000 UOK262 cells were plated in two-well chamber slides
Cancer Cell
Inhibiting ABL1 in HLRCC Cancer(Nunc Lab-Tek, Sigma-Aldrich) and treated for 6 hr with vandetanib (20 nM)
before fixation with 4% paraformaldehyde. Cells were blocked for 1 hr with
BSA (3%) and permeabilized with Triton (0.5%). Mouse anti-NRF2 antibody
(dilution, 1:100; Abcam # 62352) was added, and chamber slides were incu-
bated overnight at 4C in a humidified atmosphere. After three washes with
Tris-buffered saline and Tween 20 buffer, slides were incubated 1 hr with sec-
ondary antibody coupled to Alexa Fluor 455 (dilution 1:1,000), washed, and
mounted. Nuclei were stained with DAPI (Cell Signaling Technology). Images
were captured with a confocal microscope (Zeiss NLO510). Nuclear localiza-
tion was quantified by measuring the corrected total cell fluorescence
(CTCF) in the nuclei of the cells. Briefly, the intensity of five nuclei from ten
different fields per condition were measured using Image J. CTCF was then
calculated with the following formula: CTCF = integrated density  (area of
selected cell x mean fluorescence of background readings).
NRF2 Reporter Assay
NRF2 transcriptional activity was measured using the pGL4.37[luc2/ARE/
Hygro] vector (Promega), following the manufacturer’s protocol. Briefly,
5,000 HEK293 cells were plated in white clear-view plates (PerkinElmer) and
were transfected the following day with 100 ng of DNA per well using XTreme
Gene HP transfection reagent (Roche Applied Science). After 24 hr, cells were
treated as indicated in the figure legends. Luminescence was measured as an
indicator of NRF2 transcriptional activity using the Dual-Glo Luciferase Assay
System (Promega). The Renilla luciferase plasmid was cotransfected as rec-
ommended by the manufacturer to normalize the results.
Statistics
All values are expressed as mean ± SE. All experiments were performed three
times, with exception of the animal study which was performed two times.
Values were compared using the Student-Newman-Keul’s test; p < 0.05 was
considered significant.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and one table and can be found with this article online at
http://dx.doi.org/10.1016/j.ccell.2014.10.005.
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